| dc.description.abstract | Curcumin, the yellow pigment in the spice turmeric, has emerged as a promising anti-cancer agent due to its anti-proliferative and anti-angiogenic properties. However, curcumin′s low bioavailability and efficacy in vivo have hindered its clinical development. Therefore, we investigated bis-heterocyclic derivatives derived from monocarbonyl curcumin analogs as potential anti-cancer drug candidates. Our study found that compound HJL-A-58A, a novel bicyclic pyrazoline analog, exhibited anti-proliferative activity in cancer cell lines such as MDA-MB-231, BT549, MIA PaCa-2, PANC-1, and PC-3. Additionally, compound HJL-A-58A demonstrated anti-migratory capabilities in these five cancer cell lines. In cell cycle experiments, MIA PaCa-2 cells were arrested in the S phase in a dose-dependent manner after treatment with compound HJL-A-58A for 48 hours. Furthermore, our results indicate that compound HJL-A-58A shows effective angiogenesis inhibitory activity in tube formation assays and in ex vivo mice aortic ring assays, highlighting its potential in targeting tumor vasculature. These results underscore the therapeutic potential of HJL-A-58A in combating cancer progression through targeting cell survival, migration, and angiogenesis pathways. | en_US |